GlaxoSmithKline (GSK) seeks a novel drug or target to treat polycystic kidney disease.
ADPKD affects ~500,000 patients in US and ~10 million world-wide with limited treatment options. ADPKD patients develop progressive cyst growth in kidney over decade, eventually leading to deterioration of kidney function combined with severe pain, hematuria and fibrosis/inflammation. Two mutations (Pkd1/pkd2) account for >95% of ADPKD cases, and the dominant nature and high penetration rate of this disease affects patient families in a profoundly negative way in both health care and social interactions. There is currently no FDA approved medicine for ADPKD in US, although vasopressin antagonist and somatostatin mimetics are in phase 3 studies.
GSK aims to deliver innovative medicine to treat ADPKD based on novel mechanism of action. We are particularly interested in agents or targets that function upstream of final cellular proliferative response and have solid genetic/pharmacological evidence supporting the role of such target/agents in human ADPKD. We are also interested in mechanisms/targets that can treat both liver and kidney cyst progression.
We are open to form a partnership or alliance with perspective investigators/sponsors to pursue such new target/agents upon review and approval.
Key success Criteria
The anticipated drug target molecule(s)/gene(s) should meet the following requirements:
A different mechanism of action from that of existing drugs including vasopressin antagonist or somatostatin mimetics.
Relevant validation data with the drug or target (or a viable plan to acquire) in a human in vitro disease model where the phenotype is driven by the predominant mutations of PC1/2 that drive human disease. Although not essential, evidence of efficacy in relevant PKD animal models would be desirable.
Any technology or approach that meets the requirements will be considered.
Approaches not of Interest
Target molecule(s) with the same mechanism of action as that of existing drugs (Tolvaptan) or investigational drugs under development (Octreotide, Lanreotide, Pasireotide)
Validation data derived from animal models only
Agents/targets that exclusively target cell proliferation response, e.g. repurposed oncology compounds.
Compounds with known toxicity in chronic setting.
Items to be submitted
ANTICIPATED PROJECT PHASES OR PROJECT PLAN
Applicant organizations are required to submit non-confidential proposals.
The scientists in GlaxoSmithKline will review proposals and select candidates for further discussions.. Once candidates are selected, GSK will execute confidential disclosure agreements (CDAs) to seek further information disclosure and discuss possible research approaches.
Once the best candidates have been determined, GSK will execute research collaborations, ,joint contract research and / or licensing agreements with partners.
ITEMS TO BE INCLUDED IN THE PROPOSAL
A non-confidential proposal including the following information:
Overview of the drug target(s) (such as characteristics, superiority to existing drug targets)
Rationale and human in vitro modeling data indicating validity as a drug target (for example the data could include human genetic evidence, relevant human phenotypic readouts related to the mechanism of interest in human cell types, with appropriate controls)
Current research and development stage
Future research and development plans
An overview of your organisation and your experience with target validation
Any request concerning the structure of collaboration
Related intellectual property
Client Point of Contact
Preferred Collaboration Types
To Be Negotiated
Area of Interest
Engineering Science and Materials > Engineering Science and Materials-General > Engineering Science and Materials-All disciplines
Pharmacy and Pharmaceutical Sciences > Pharmaceutics and Drug Design > Pharmaceutics and Drug Design-All disciplines
Pharmacy and Pharmaceutical Sciences > Pharmacy and Pharmaceutical Sciences-General > Pharmacy and Pharmaceutical Sciences -All disciplines
Biology-General > General Biology-General > General Biology-All disciplines
Bioinformatics > Application Areas > Gene and protein expression
Pharmacy and Pharmaceutical Sciences > Other Pharmacy and Pharmaceutical Sciences > Other Pharmacy and Pharmaceutical Sciences-All disciplines
Dentistry > General Dentistry > General Dentistry-All disciplines
Pharmacology > Drug Discovery, Drug Development, and Regulatory Affairs > Drug Discovery, Drug Development, and Regulatory Affairs- All disciplines
Biotechnology > Modification Methods > Genetic Modification and Engineering
Medical Specialties > Internal Medicine > Internal Medicine-All disciplines
Engineering-Biomedical > Biomedical Engineering-General > Biomedical Engineering and Bioengineering-All disciplines
Genetics and Genomics > Molecular Genetics > Microbial Genetic Composition and Function
Medical Sciences > Medical Molecular Biology > Medical Molecular Biology-All disciplines